A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
Clinical trial NCT05441475 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT05441475
- Sponsor
- Abbisko Therapeutics Co, Ltd
- Status
- ENROLLING_BY_INVITATION
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-30
- Primary completion
- 2028-12-31
- Enrollment
- 118
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.